^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BSK-01

    i
    Associations
    News

    Trials

    Company:
    Kiromic
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Consolidation Therapy in Patients With Hematologic Malignancies (NCT02709993)
    Phase 1/2
    Kiromic, Inc.
    Withdrawn
    Last update posted :
    10/14/2019
    Initiation :
    07/28/2017
    Primary completion :
    10/31/2020
    Completion :
    10/31/2020
    HLA-A • PTTG1
    |
    HLA-A*02 • HLA-A*24
    |
    cyclophosphamide • BSK-01
    Therapy for Progressive and/or Refractory Hematologic Malignancies (NCT02223312)
    Phase 1/2
    Kiromic, Inc.
    Withdrawn
    Last update posted :
    08/28/2018
    Initiation :
    07/28/2017
    Primary completion :
    10/31/2018
    Completion :
    01/31/2019
    CSF2 • PTTG1
    |
    HLA-A*24
    |
    cyclophosphamide • BSK-01
    Consolidation Therapy in Patients With Metastatic Solid Malignancies (NCT02705703)
    Phase 1/2
    Kiromic, Inc.
    Withdrawn
    Last update posted :
    08/28/2018
    Initiation :
    07/28/2017
    Primary completion :
    10/31/2018
    Completion :
    01/31/2019
    HER-2 • HLA-A • CTAG1B
    |
    HER-2 expression • HLA-A*02 • HLA-A*24
    |
    cyclophosphamide • BSK-01